If you talk about Northern United Pharmaceutical, it is still very valuable.

Tens of thousands of acres of land are just obtained, not counting for the time being. Tens of thousands of technical workers cannot be regarded as simply a burden. After all, they are all technical workers.

However, the reality is that China in the 1980s had no shortage of skilled workers. So many workers in the third-tier and third-tier lines would have been unemployed. If it weren’t for the establishment of the Chemical Pharmaceutical Revitalization Office and Northern United Pharmaceutical, thousands of workers in North China Pharmaceutical would have been facing unemployment in a few years.

To be more precise, the tens of thousands of workers mixed together are like a pile of unsorted dates. If the stalls are not separated, the rotten dates will sooner or later rotten dates.

No one expected that such a Northern United Pharmaceutical could be worth $60 million and then collect real money from Jielikan.

They are not interested in Jielikang, whether it is Northern United Pharmaceutical or Chemical Pharmaceutical Revitalization Office. The only thing they are interested in is the medicines in Yang Rui's hands.

Just the profit from production and sales can make them profit back.

Only the new drugs developed by Yang Rui can earn them back 30 million US dollars.

Pharmaceutical companies' desire for new drugs is difficult for workers in other industries to understand.

Thousands of pharmaceutical companies around the world are usually within a hundred pharmaceutical companies that are capable of developing new drugs. Except for single-digit generic drug companies, the remaining double-digit pharmaceutical companies can only invest in three or five pure new drugs in the market every year.

At this time, whoever holds the new medicine will simply have the power of life and death.

It is either symbolic, or the actual power of life and death.

For example, Gaucher's disease, although it is a rare disease, it is also a rare disease with a high incidence rate. There are hundreds of thousands of patients around the world, but in the absence of suitable drugs, the life cycle of Gaucher's patients is only 10 years after the onset of the disease, which basically does not exceed 20 years.

At this time, there was a message that everyone was unwilling to think about. If there were really special medicines, there would not be only hundreds of thousands of Gauche patients in the world.

And so many people obviously cannot get medicine at one time.

Even from a security perspective, countries will not let new drugs be released at home in one go.

At this time, the pharmaceutical company actually controls the life and death of these Gaucher patients.

In which country they first apply for sales, the Gaucher patients in which country will be treated in advance. This not only means a higher survival rate, but also means less pain and improve quality of life.

No one wants to live with a sick body.

From the perspective of consumers and hospitals, they also expect special drugs to appear.

Pharmaceutical companies that can always produce new and good medicines will be more popular with hospitals and doctors, which is a unique stature of pharmaceutical companies. When necessary, pharmaceutical companies can even conduct bundled sales, stipulating that as many special medicines as you buy, you will have to buy as much ordinary medicine as you buy...

Where regulations are not strictly restricted, whoever holds the power of life and death is qualified to make money.

How much is 500,000 lives worth?

Is it more than $100 per person?

Is $200 per person expensive?

In the modern consumption system, production costs are just a small part of pharmaceutical companies, and sales, R&D and management costs are the places where the most expenses are spent.

A new drug may not make pharmaceutical companies rich in one breath. After all, a bombshell with annual sales of US$1 billion is a minority, but a continuous stream of new drugs is the meaning of the survival of pharmaceutical companies.

It is not only the significance of the survival of pharmaceutical companies themselves, but also the view of it by the public, society and the state.

If a pharmaceutical company cannot produce a new drug in five years, no matter whether it is made by itself or bought, even if it makes a lot of money in other income, investors will always be worried about it.

If a pharmaceutical company cannot produce a new drug in 10 years, even if the investors themselves don’t say it, the company itself will not be able to hold on.

In an industry that sells health and life, there are so many ways for pharmaceutical companies to make money.

The annual treatment costs of certain special rare drugs can even be paid up to one million US dollars, which is a pervert. Pharmaceutical companies in war-torn areas have never appeared with kind faces. Pharmaceutical companies in bustling cities are even more good at doing things that are thrifty.

However, no matter how the pharmaceutical company wants to make money, you must have the medicine in your hands first.

New drugs with a 15-year patent period and rare drugs with a 25-year patent period are weapons in the hands of pharmaceutical companies.

The 15-year-old boy is willing to pay for the weapons of his thief, and the pharmaceutical company is willing to pay for a new drug.

The little thoughts of Northern United Pharmaceuticals were like ice and snow falling on the oven under the pressure of Jielikang, and disappeared without a trace in a moment.

However, the funds allocated to the Ion Channel Laboratory account in advance were still only a pitiful $200,000.

In the words of Comrade Wang Gaohan, the new general manager of Northern United Pharmaceutical, “If it’s not enough, say hello and the money will come.”

The project team responsible for recombinant DNA is naturally full of complaints, and Gu Qiang even complained: "The 200,000 US dollars is not enough to buy a fluorescent microplate reader, so it doesn't have to start, it's over."

Yang Rui chose the special drug for Gaucher's disease as an enzyme alternative. It is such a simple principle.

However, it is extremely difficult to make glucerebrosidase combined with humans - and no matter how this step is performed, instruments such as fluorescence microplate reader are required.

Glutacerebrosidase can't be seen in the human eye.

In addition, higher-resolution ultraviolet-visible spectrophotometers, new electrophoresis instruments with higher efficiency, etc. are also essential expenses.

Although laboratories can share these commonly used equipment, grabbing instruments is obviously not the right choice during the compact time of new drug development.

In addition, the scale of the ion channel laboratory is growing, and new instruments are needed to develop new projects, even repeated instruments are inevitable. Just like the simplest microscope, you can't wait in line for a group of experimental dogs to use.

Some domestic project teams are so poor that they are so poor that Yang Rui is not going to let the ion channel laboratory live the hard days of waiting for the instrument at two o'clock in the morning.

Whoever loves who is past.

"Take money from the laboratory's general ledger and return it to them $200,000." Yang Rui quickly made the decision and called Xu Zhengping again, saying: "You go and contact a foreign evaluation company to evaluate the price of our current recombinant DNA project team, the alternative solution to glucerebrosidase."

"What is that?" Xu Zhengping was stunned.

"It's just to find a foreign company to come over and let them see how much the things our project team makes are worth in the market." Yang Rui paused and said, "People from Northern United Pharmaceuticals are used to life in state-owned enterprises, and they still want to get research results at the cost price. 200,000 or 2 million yuan is just buying a head up."

Xu Zhengping went to look for it with some hesitation. He didn't know how strong Yang Rui's decision was to oppress Northern United Pharmaceutical. In fact, there are basically no companies in China that can understand this now.

In this era when the company set up a research institute, the value of research results has always fluctuated at cost prices.

Unfortunately, Yang Rui was not prepared to talk to them about cost issues.
Chapter completed!